These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21181036)

  • 1. [Leprosy reactions in discharged patients following cure by multidrug therapy].
    Souza LW
    Rev Soc Bras Med Trop; 2010; 43(6):737-9. PubMed ID: 21181036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late leprosy reaction presenting as erythema multiforme-like erythema nodosum leprosum with underlying rifampicin resistance and its potential implications.
    Sardana K; Kulhari A; Mathachan SR; Khurana A; Bansal P; Ahuja A; Lavania M; Ahuja M
    Int J Mycobacteriol; 2020; 9(2):226-228. PubMed ID: 32474551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M; Berhe D
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactions following completion of 1 and 2 year multidrug therapy (MDT).
    Balagon MV; Gelber RH; Abalos RM; Cellona RV
    Am J Trop Med Hyg; 2010 Sep; 83(3):637-44. PubMed ID: 20810832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognizing and managing the immunologic reactions in leprosy.
    Kamath S; Vaccaro SA; Rea TH; Ochoa MT
    J Am Acad Dermatol; 2014 Oct; 71(4):795-803. PubMed ID: 24767732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactional states in multibacillary Hansen disease patients during multidrug therapy.
    Nery JA; Vieira LM; de Matos HJ; Gallo ME; Sarno EN
    Rev Inst Med Trop Sao Paulo; 1998; 40(6):363-70. PubMed ID: 10436656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse rates following leprosy multidrug therapy.
    Suite M
    West Indian Med J; 2000 Sep; 49(3):210-1. PubMed ID: 11076211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary results of clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): reactions frequency in multibacillary patients.
    Penna ML; Buhrer-Sékula S; Pontes MA; Cruz R; Gonçalves Hde S; Penna GO
    Lepr Rev; 2012 Sep; 83(3):308-19. PubMed ID: 23356032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leprosy reactions in postelimination stage: the Bangladesh experience.
    Mowla MR; Ara S; Mizanur Rahman AFM; Tripura SP; Paul S
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):705-711. PubMed ID: 27859670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiological characteristics of leprosy reactions: 15 years experience from north India.
    Kumar B; Dogra S; Kaur I
    Int J Lepr Other Mycobact Dis; 2004 Jun; 72(2):125-33. PubMed ID: 15301592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Leprosy reactions in a Colombian national reference centre].
    Nova J; Sánchez G
    Biomedica; 2013; 33(1):99-106. PubMed ID: 23715312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial to compare cure and relapse rate of paucibacillary multidrug therapy with monthly rifampicin, ofloxacin, and minocycline among paucibacillary leprosy patients in Agra District, India.
    Kumar A; Girdhar A; Girdhar BK
    Indian J Dermatol Venereol Leprol; 2015; 81(4):356-62. PubMed ID: 26144850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-course multi-drug therapy for leprosy patients.
    Puavilai S; Timpatanapong P
    J Med Assoc Thai; 1989 Jan; 72(1):33-6. PubMed ID: 2656897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-duration therapy (FDT) in multibacillary leprosy; efficacy and complications.
    Vijayakumaran P; Jesudasan K; Manimozhi N
    Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):123-7. PubMed ID: 8690969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
    Groenen G; Janssens L; Kayembe T; Nollet E; Coussens L; Pattyn SR
    Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):236-44. PubMed ID: 3722962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six months MDT for paucibacillary leprosy: nerve damage and relapse.
    Wheate HW
    Lepr Rev; 1986 Jun; 57(2):179. PubMed ID: 3747708
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison between lymecycline with multidrug therapy and standard multidrug regimen (WHO-MDT) in the treatment of multibacillary leprosy patients: a retrospective cohort study.
    Diaz JCD; Abad-Venida ML; Espinoza-Thaebtharm A; Cathryn Salonga ME; Abad-Casintahan MF
    Int J Dermatol; 2023 Sep; 62(9):1186-1192. PubMed ID: 37408116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rare variant of erythema nodosum leprosum: a case report.
    Dave S; Thappa DM; Nori AV; Jayanthi S
    Dermatol Online J; 2003 Dec; 9(5):11. PubMed ID: 14996384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.